We proposed that lung cancer patients with the expression profile of ZNF322Ahigh/Shhhigh/CD31high may be selected for further treatment with Shh neutralizing antibodies, although targeting Shh via antibodies has not reached human trials 40,41. This evidence concerns the gene SHH and lung cancer.